drug designation News
-
Showcase
Zeneo® Midazolam Earns The Orphan Drug Designation
The American Food and Drug Administration (FDA) has granted Orphan Drug Designation to ZENEO® Midazolam for the treatment of status epilepticus (epileptic seizure lasting longer than 5 minutes). The orphan designation for ZENEO® Midazolam improves Crossject’s international visibility and gives impetus to its current negotiations for partnerships with pharmaceutical laboratories. ...
By Crossject
-
FDA Orphan Drug Designation Granted
The orphan drug designation will provide SFA Therapeutics with significant drug development and tax advantages as well as an expanded period of market ...
-
Creative Biostructure Provides Solutions for Drug Design with Structure-based Drug Design Platform
Creative Biostructure Drug Discovery, a sub-brand of Creative Biostructure that applies its expertise in structural biology and membrane proteins to the drug discovery process, has developed MagHelix™ Structural Biology and SBDD Platform that covers all the mainstream technologies needed to successfully determine the 3D structure of biological macromolecules. Structure-based drug design ...
-
Makya Webinar 2021
Topic: Makya: AI-driven de novo drug design and multi-parametric optimisation Recording Duration: 56:50 Webinar Start Time: Dec 7, 2021, 10 - 11 AM CET & 5 - 6 PM CET Access to the Recorded ...
By Iktos
-
3DBio Therapeutics Receives Orphan Drug Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients
3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced it has received Orphan Drug Designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia. Microtia is a rare congenital disorder causing the outer ear (auricle) to be smaller than typical, misshapen, and sometimes ...
-
Structure-based Drug Design is an Essential Tool for Quicker and More Cost-Efficient Lead Discovery
As an active player in the chemical industry, Alfa Chemistry decided to combine the power of computational chemistry with drug design and synthesis. This move aims to largely enhance the overall drug discovery efficiency and open up new possibilities for the pharmaceutical industry. Fairly recently, the company launched a series of structure-based drug design (SBDD) services, showing capabilities ...
-
CD Formulation Provides Tailor-made Solutions for Thickener Excipients for Drug Development
To help accelerate the drug design process is always the goal of CD Formulation, a New York-based CRO company. As we put 2021 behind us, the aim of CD Formulation remains unchanged and there is even greater motivation to be a more active player in the pharmaceutical industry. Therefore, the company recently announces to start to provide tailor-made solutions for the manufacturing of thickener ...
-
TIKOMED granted Orphan Medicinal Drug Designation for ILB® for the treatment of amyotrophic lateral sclerosis by the European Commission
TIKOMED, a Swedish privately-held biopharmaceutical company today announced that the European Commission has granted Orphan Drug Designation to its lead drug candidate ILB® for the treatment of patients with amyotrophic lateral sclerosis (ALS) – a terminal, neurodegenerative disease where most patients die of respiratory muscle weakness in less than three to five years from symptom ...
By TIKOMED AB
-
Iktos Announces a Collaboration With Ono in Artificial Intelligence for New Drug Design
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design today announced a collaboration agreement with Ono Pharmaceuticals Co., Ltd., a leading pharmaceutical company based in Japan with a focus on innovative medicines dedicated to the fight against disease and pain. Under the agreement, Iktos will apply its de novo ligand and structure-based generative modelling ...
By Iktos
-
SilcsBio and Helix BioStructures Launch Partnership to Collaborate in Fueling Pharmaceutical Drug Design Opportunities
August 29, 2022, Baltimore, MD and Indianapolis, IN – SilcsBio, a technology company that develops and markets software and services for structure-based drug design, today announced the launch of a partnership with Helix BioStructures, a pharmaceutical-biotech contract research organization that provides high-quality, integrated drug discovery services to the pharmaceutical community in the ...
-
CD ComputaBio Has Launched Hybrid Method for Virtual Screening Service to Assist Scientists
Earlier this month, CD ComputaBio, a senior US provider of computational biology services, announced that it had expanded its service line by providing hybrid method for virtual screening service to customers around the world. Since its establishment, CD ComputaBio has been committed to providing high-quality and all-round services for scientists and researchers to help them make rapid ...
-
CD ComputaBio Announces 3D-QSAR Service for Drug Design and Screening
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company has recently launched 3D-QSAR services for scientists to accelerate the drug development process. Quantitative ...
-
EPSRC-funded software for research communities project to position OpenMM community at forefront of latest CADD developments
Atomistic simulations constitute one of the primary uses of high-performance computing in research, as they establish the foundation of Research and Development procedures in the chemical and biological sectors. Among the plethora of open-source academic software, OpenMM has the quickest rate of growth due to its excellent tradeoff between extensibility via a robust user interface, and ...
-
Potential cell therapy for Epidermolysis Bullosa (EB)
In partnership with Mesoblast Limited, JCR Pharmaceuticals has filed to extend the marketing approval of TEMCELL, a mesenchymal stem cell (MSC) wound healing product for patients with Epidermolysis Bullosa (EB). JCR has received an orphan drug designation for subcutaneous treatment of TEMCELL for EB, and are currently seeking a label extension for intravenous delivery of TEMCELL in Japan. There ...
By IMAPAC
-
Profacgen Updated Its Membrane Protein Modeling Service Recently
Profacgen, a state-of-the-art protein service provider that provides custom protein services in the biological sciences, recently updated its membrane protein modeling service to better assist scientists in the field of structure-based protein engineering. Membrane proteins account for one third of all genes in the human genome, and they play critical roles as receptors, enzymes, ion channels, ...
By Profacgen
-
CD ComputaBio Unveils Ligand-based Pharmacophore Model Service for Drug Design and Screening
CD ComputaBio, a reliable computational biology service provider located in New York, is always hammering away at research and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. The company recently announced the launch of ligand-based pharmacophore model service for scientists to accelerate the ...
-
Alfa Chemistry Combines the Power of Computational Chemistry for Multiple Medical Applications
Computational chemistry, a branch of chemistry that applies computer simulation to assist in solving chemical problems, is a heated topic in the modern scientific community. Possessing a powerful team of experts in chemistry, biology, mathematics, crystallography, and pharmacology, Alfa Chemistry focuses on combining the power of computational chemistry with a variety of research focuses on ...
-
Enable Injections brings in $215M
Enable Injections has raised a $215 million Series C led by Magnetar Capital. The Cincinnati-based company is a developer of wearable drug delivery systems designed to administer high volumes of therapeutics. Select Additional Investors Cintrifuse, Ohio Innovation Fund, Squarepoint Capital, Woody Creek Capital Partners ...
-
Sygnature Discovery to Deploy Iktos’s AI for Drug Design Software Makya
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design and Sygnature Discovery, a leading integrated drug discovery CRO headquartered in Nottingham, UK, with expertise across a range of therapeutic and biological target classes today announced a collaboration agreement in AI for new drug design. Under the 3-year agreement, Sygnature will deploy Iktos’ de novo ...
By Iktos
-
Accelerating Drug Development with CD ComputaBio's Advanced Drug Design and CADD Solutions
CD ComputaBio, a reputable computational service provider in the field of biology, is dedicated to supporting research and trials by offering access to the latest software, technologies, and expertise at competitive prices and with fast turnaround times for researchers. Recently, the company introduced a series of state-of-the-art services in Drug Design and Computer-Aided Drug Design (CADD) with ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you